keyword
MENU ▼
Read by QxMD icon Read
search

abatacept

keyword
https://www.readbyqxmd.com/read/29146547/a-gene-module-associated-with-dysregulated-tcr-signaling-pathways-in-cd4-t-cell-subsets-in-rheumatoid-arthritis
#1
Shuji Sumitomo, Yasuo Nagafuchi, Yumi Tsuchida, Haruka Tsuchiya, Mineto Ota, Kazuyoshi Ishigaki, Shinichiro Nakachi, Rika Kato, Keiichi Sakurai, Norio Hanata, Shoko Tateishi, Hiroko Kanda, Akari Suzuki, Yuta Kochi, Keishi Fujio, Kazuhiko Yamamoto
We analyzed the transcriptome of detailed CD4(+) T cell subsets including them after abatacept treatment, and examined the difference among CD4(+) T cell subsets and identified gene sets that are closely associated disease activity and abatacept treatment. Seven CD4(+) T cell subsets (naive, Th1, Th17, Th1/17, nonTh1/17, Tfh and Treg) were sorted from PBMCs taken from 10 RA patients and 10 healthy controls, and three RA patients donated samples before and 6 months after abatacept treatment. Paired-end RNA sequencing was performed using HiSeq 2500...
November 13, 2017: Journal of Autoimmunity
https://www.readbyqxmd.com/read/29146040/-effectiveness-therapeutic-maintenance-and-reasons-for-stopping-tocilizumab-tcz-a-retrospective-and-monocentric-study-in-88%C3%A2-patients-followed-for-rheumatoid-arthritis-ra-at-the-reims-university-hospital
#2
Clément Chopin, Loïc Pauvelle, Sarah Jaulerry, Pascal Brochot, Jean-Paul Eschard, Jean-Hugues Salmon
OBJECTIVE: Study the therapeutic maintenance, efficacy and reasons for tocilizumab stop in daily practice. PATIENTS AND METHODS: A monocentric, retrospective study of patients treated for rheumatoid arthritis who received at least one TCZ infusion between January 2009 and December 2015. Therapeutic maintenance was evaluated using the Kaplan-Meier method. The efficacy of TCZ was measured by DAS28 and the EULAR response. Reasons for stopping and new treatment lines were also collected...
October 18, 2017: Thérapie
https://www.readbyqxmd.com/read/29146018/biological-treatments-in-giant-cell-arteritis-takayasu-arteritis
#3
Maxime Samson, Georgina Espígol-Frigolé, Nekane Terrades-García, Sergio Prieto-González, Marc Corbera-Bellalta, Roser Alba-Rovira, José Hernández-Rodríguez, Sylvain Audia, Bernard Bonnotte, Maria C Cid
Giant cell arteritis (GCA) and Takayasu arteritis (TAK) are the two main large vessel vasculitides. They share some similarities regarding their clinical, radiological and histological presentations but some pathogenic processes in GCA and TAK are activated differently, thus explaining their different sensitivity to biological therapies. The treatment of GCA and TAK essentially relies on glucocorticoids. However, thanks to major progress in our understanding of their pathogenesis, the role of biological therapies in the treatment of these two vasculitides is expanding, especially in relapsing or refractory diseases...
November 13, 2017: European Journal of Internal Medicine
https://www.readbyqxmd.com/read/29127626/impact-of-infliximab-and-etanercept-biosimilars-on-biological-disease-modifying-antirheumatic-drugs-utilisation-and-nhs-budget-in-the-uk
#4
Mohammed I Aladul, Raymond W Fitzpatrick, Stephen R Chapman
OBJECTIVE: Biological disease-modifying antirheumatic drugs (bDMARDs) are effective but expensive options for treating rheumatoid arthritis. The introduction of infliximab and etanercept biosimilars presents a significant potential cost saving in a financially constrained health system such as the National Health Service (NHS) in the UK. This study examines the impact of the introduction of infliximab and etanercept biosimilars on the utilisation of bDMARDs and subsequent budget impact...
November 10, 2017: BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
https://www.readbyqxmd.com/read/29102157/the-ultrasound-clinical-arthritis-activity-us-clara-index-properties-of-a-new-composite-disease-activity-index-for-rheumatoid-arthritis
#5
Fausto Salaffi, Marco Di Carlo, Florenzo Iannone, Anna Laura Fedele, Oscar Massimiliano Epis, Raffaele Pellerito, Rosario Foti, Giuseppe Passiu, Leonardo Punzi, Federica Furini, Piercarlo Sarzi-Puttini, Antonio Carletto, Elisa Gremese, Giovanni Lapadula, Gianfranco Ferraccioli
OBJECTIVE: To assess validity, responsiveness and interpretability of the UltraSound-CLinical ARthritis Activity (US-CLARA) index in patients with rheumatoid arthritis (RA). METHODS: In this longitudinal study were involved RA patients starting treatment with abatacept. Subjects were followed along three visits in the first 6 months of therapy and underwent a comprehensive clinimetric evaluation. Validity was explored correlating the baseline scores and the cumulative inflammatory burden of the US-CLARA with the other composite indices applied...
September 28, 2017: Seminars in Arthritis and Rheumatism
https://www.readbyqxmd.com/read/29096669/anti-carbamylated-protein-antibodies-precede-disease-onset-in-monkeys-with-collagen-induced-arthritis
#6
Marije K Verheul, Michel P M Vierboom, Bert A 't Hart, Rene E M Toes, Leendert A Trouw
BACKGROUND: Rheumatoid factor (RF), anti-citrullinated protein antibodies (ACPA) and anti-carbamylated protein (anti-CarP) antibodies are rheumatoid arthritis (RA)-associated autoantibodies. Besides their presence in human serum, anti-CarP antibodies have also been described in rodent models of arthritis, while ACPA are not consistently detectable. Data on these RA-associated autoantibodies in primates are not available. Therefore, we investigated the presence of RF, anti-CarP antibodies and ACPA in rhesus monkeys before and after collagen-induced arthritis immunizations...
November 2, 2017: Arthritis Research & Therapy
https://www.readbyqxmd.com/read/29093151/effect-of-anticitrullinated-protein-antibody-status-on-response-to-abatacept-or-antitumor-necrosis-factor-%C3%AE-therapy-in-patients-with-rheumatoid-arthritis-a-us-national-observational-study
#7
Leslie R Harrold, Heather J Litman, Sean E Connolly, Sheila Kelly, Winnie Hua, Evo Alemao, Lisa Rosenblatt, Sabrina Rebello, Joel M Kremer
OBJECTIVE: Assess whether baseline anticyclic citrullinated peptide antibodies (anti-CCP) status is associated with treatment response in patients with rheumatoid arthritis (RA) initiating abatacept (ABA) or a tumor necrosis factor-α inhibitor (TNFi). METHODS: Using the Corrona RA registry, patients were identified who initiated ABA or a TNFi (June 2004-January 2015), had a followup visit 6 months (± 3 mos) after initiation, and anti-CCP measured at or prior to initiation...
November 1, 2017: Journal of Rheumatology
https://www.readbyqxmd.com/read/29081616/biological-response-modifiers-in-rheumatoid-arthritis-systematic-review-and-meta-analysis-of-safety
#8
Nitishkumar D Tank, Bharti N Karelia, Bhavisha N Vegada
OBJECTIVE: To analyze available evidence on the safety of different biological response modifiers which are used for a treatment of rheumatoid arthritis (RA). MATERIALS AND METHODS: We searched systematically for randomized controlled clinical trials on treatment of RA with different biological response modifiers, followed by a systematic review with meta-analysis. Trials were searched from MEDLINE and Cochrane Library databases. The following safety parameters reported in the selected trials were analyzed: number of patients suffering any adverse event (AE), withdrawal due to AEs, serious AE (SAEs), infections, serious infections, infusion reactions, injection site reactions, malignancies, and overall mortality...
July 2017: Journal of Pharmacology & Pharmacotherapeutics
https://www.readbyqxmd.com/read/29077694/practical-approach-to-the-evaluation-and-management-of-rheumatoid-arthritis-interstitial-lung-disease-based-on-its-proven-and-hypothetical-mechanisms
#9
Francisco Paulin, Alejandra Babini, Marta Mamani, Juan Mercado, Fabián Caro
The prevalence of interstitial lung disease in patients with rheumatoid arthritis varies from 10 to 42%. Rheumatoid arthritis patients with interstitial lung disease have three times the risk of death compared with those without the disease. Prognosis seems to be related to the high-resolution computed tomography pattern. Usual interstitial pneumonia pattern, resembling idiopathic pulmonary fibrosis, carries a worse prognosis. Validated strategies to identify different phenotypes and assess the disease activity in rheumatoid arthritis interstitial lung disease are lacking...
September 2017: Revista de Investigación Clínica; Organo del Hospital de Enfermedades de la Nutrición
https://www.readbyqxmd.com/read/29069471/serious-infusion-related-reaction-after-rituximab-abatacept-and-tocilizumab-in-rheumatoid-arthritis-prospective-registry-data
#10
Jean-Hugues Salmon, Jeanne-Marie Perotin, Jacques Morel, Moustapha Dramé, Alain Cantagrel, Liana Euller Ziegler, Philippe Ravaud, Jean Sibilia, Isabelle Pane, Xavier Mariette, Jacques-Eric Gottenberg
Objective: The aim was to evaluate the incidence of serious infusion-related reactions (SIRRs) in RA treated by non-TNF-targeted biologics. Methods: We analysed data from three independent prospective registers, namely autoimmunity and rituximab, Orencia (abatacept) and RA (ORA) and Registry RoAcTEmra (tocilizumab), promoted by the French Society of Rheumatology and including patients with RA. SIRRs were defined by an occurrence during or within 24 h of an infusion and requiring discontinuation of treatment...
October 23, 2017: Rheumatology
https://www.readbyqxmd.com/read/29046115/bone-and-the-immune-system
#11
M Neale Weitzmann
Osteoporosis increases fracture risk, a cause of crippling morbidity and mortality. The immunoskeletal interface (ISI) is a centralization of cell and cytokine effectors shared between skeletal and immune systems. Consequently, the immune system mediates powerful effects on bone turnover. Physiologically, B cells secrete osteoprotegerin (OPG), a potent anti-osteoclastogenic factor that preserves bone mass. However, activated T cells and B cells secrete pro-osteoclastogenic factors including receptor activator of Nuclear factor-kappaB (NF-kB) ligand (RANKL), Interleukin (IL)-17A, and tumor necrosis factor (TNF)-α promoting bone loss in inflammatory states such as rheumatoid arthritis...
January 1, 2017: Toxicologic Pathology
https://www.readbyqxmd.com/read/29043142/costimulation-pathway-blockade-in-kidney-transplant-recipients-with-de-novo-rheumatoid-arthritis
#12
Mohamed Sheta, Samy Riad, Udayakumar Deepak, Naim Issa, Mark Birkenbach, Hassan N Ibrahim, Aleksandra Kukla
The best approach to treatment of de-novo rheumatoid arthritis in solid organ transplant recipients on typical immunosuppression is not well established. The use of biologics targeting specific cell types, cytokines, and immunological pathways has been gaining interest in the treatment of both, auto- and alloimmunity. We present a case of de-novo rheumatoid arthritis in a kidney transplant recipient 10 years post-transplant while receiving cyclosporine, mycophenolate mofetil, and also prednisone. Initial presentation included features of polymyalgia rheumatica and nephrotic range proteinuria...
2017: Clin Nephrol Case Stud
https://www.readbyqxmd.com/read/29039054/treatment-persistence-and-healthcare-costs-among-patients-with-rheumatoid-arthritis-changing-biologics-in-the-usa
#13
Benjamin Chastek, Chieh-I Chen, Clare Proudfoot, Shraddha Shinde, Andreas Kuznik, Wenhui Wei
INTRODUCTION: After a patient with rheumatoid arthritis (RA) fails tumor necrosis factor inhibitor (TNFi) treatment, clinical guidelines support either cycling to another TNFi or switching to a different mechanism of action (MOA), but payers often require TNFi cycling before they reimburse switching MOA. This study examined treatment persistence, cost, and cost per persistent patient among MOA switchers versus TNFi cyclers. METHODS: This study of Commercial and Medicare Advantage claims data from the Optum Research Database included patients with RA and at least one claim for a TNFi (adalimumab, certolizumab pegol, etanercept, golimumab, or infliximab) between January 2012 and September 2015 who changed to another TNFi or a different MOA therapy (abatacept, tocilizumab, or tofacitinib) within 1 year...
October 16, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/29037899/the-management-of-first-line-biologic-therapy-failures-in-rheumatoid-arthritis-current-practice-and-future-perspectives
#14
REVIEW
Ennio Giulio Favalli, Maria Gabriella Raimondo, Andrea Becciolini, Chiara Crotti, Martina Biggioggero, Roberto Caporali
The introduction of biologic disease-modifying anti-rheumatic drugs (bDMARDs) has dramatically changed the management of rheumatoid arthritis (RA). However, in a real-life setting about 30-40% of bDMARD treated patients experience drug discontinuation because of either inefficacy or adverse events. According to international recommendations, to date the best strategy for managing first-line bDMARD failures has not been defined yet and available data (especially on TNF inhibitors [TNFis]) seem to drive toward a personalized approach for the individual patient...
October 14, 2017: Autoimmunity Reviews
https://www.readbyqxmd.com/read/29024421/generalized-estimating-equation-model-to-compare-drug-effects-on-synovitis-of-the-dominant-wrist-in-severe-rheumatoid-arthritis-between-tocilizumab-versus-adalimumab-versus-abatacept-using-high-resolution-ultrasound
#15
Ying-Chou Chen, Wen-Chan Chiu, Fu-Mei Su, Jia-Feng Chen
PURPOSE: The use of biological agents has revolutionized the treatment of rheumatoid arthritis (RA). However, details of serial synovial changes in imaging evaluation are unclear. Using power Doppler (PD) ultrasound, this study aimed to evaluate the comparative efficacy of biologicals for patients with refractory RA, with the hope that these findings could aid in clinical decision making. METHODS: Patients with RA who received abatacept, adalimumab or tocilizumab therapy were enrolled...
October 12, 2017: International Journal of Rheumatic Diseases
https://www.readbyqxmd.com/read/29023282/abatacept-monotherapy-versus-abatacept-plus-methotrexate-for-treatment-refractory-rheumatoid-arthritis
#16
Tristan Pascart, Peggy Philippe, Elodie Drumez, Xavier Deprez, Bernard Cortet, Alain Duhamel, Eric Houvenagel, René-Marc Flipo
BACKGROUND: Methotrexate combination therapy improves abatacept efficacy as a first-line biologic agent for the treatment of rheumatoid arthritis, but it is unclear when abatacept is used later on, particularly after non-TNF inhibitor (TNFi) failure. STUDY QUESTION: The objective of this study was to determine whether treatment response after non-TNFi inadequate response is different in patients with rheumatoid arthritis (RA) treated with abatacept in combination with or not with methotrexate...
September 12, 2017: American Journal of Therapeutics
https://www.readbyqxmd.com/read/28993346/abatacept-in-the-treatment-of-adult-dermatomyositis-and-polymyositis-a-randomised-phase-iib-treatment-delayed-start-trial
#17
Anna Tjärnlund, Quan Tang, Cecilia Wick, Maryam Dastmalchi, Herman Mann, Jana Tomasová Studýnková, Radka Chura, Nicola J Gullick, Rosaria Salerno, Johan Rönnelid, Helene Alexanderson, Eva Lindroos, Rohit Aggarwal, Patrick Gordon, Jiri Vencovsky, Ingrid E Lundberg
OBJECTIVES: To study the effects of abatacept on disease activity and on muscle biopsy features of adult patients with dermatomyositis (DM) or polymyositis (PM). METHODS: Twenty patients with DM (n=9) or PM (n=11) with refractory disease were enrolled in a randomised treatment delayed-start trial to receive either immediate active treatment with intravenous abatacept or a 3 month delayed-start. The primary endpoint was number of responders, defined by the International Myositis Assessment and Clinical Studies Group definition of improvement (DOI), after 6 months of treatment...
October 9, 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/28980085/real-world-experience-of-tocilizumab-in-rheumatoid-arthritis-sub-analysis-of-data-from-the-italian-biologics-register-gisea
#18
F Iannone, G Ferraccioli, L Sinigaglia, E G Favalli, P Sarzi-Puttini, F Atzeni, R Gorla, C Bazzani, M Govoni, I Farina, E Gremese, A Carletto, A Giollo, M Galeazzi, R Foti, L Bianchino, L La Grasta, G Lapadula
To assess the long-term effectiveness and safety of tocilizumab, abatacept, and tumor necrosis factor-α inhibitors (TNFi), in the Italian real-world setting of rheumatoid arthritis (RA). The records of adult RA patients from the Italian biologics' registry Gruppo Italiano Studio Early Arthritis (GISEA) were analyzed. Demographic and clinical data were obtained at entry. The disease remission rate (28-joint disease activity score calculated using the erythrocyte sedimentation rate [DAS28-ESR] ≤ 2.6) and frequency of adverse events (AEs) were evaluated at 2 years...
October 5, 2017: Clinical Rheumatology
https://www.readbyqxmd.com/read/28975211/malignant-neoplasms-in-patients-with-rheumatoid-arthritis-treated-with-tumor-necrosis-factor-inhibitors-tocilizumab-abatacept-or-rituximab-in-clinical-practice-a-nationwide-cohort-study-from-sweden
#19
Hjalmar Wadström, Thomas Frisell, Johan Askling
Importance: Considering the widespread and increasing use of biological immunomodulators (biological disease-modifying antirheumatic drugs [bDMARDs]) to treat chronic inflammatory conditions, and the concern that immunomodulation may alter cancer risk and progression, the limited available data on use of these therapies as used in clinical practice and cancer risks are a concern. Objective: To assess the risk of incident malignant neoplasms in patients with rheumatoid arthritis (RA) treated with bDMARDs...
November 1, 2017: JAMA Internal Medicine
https://www.readbyqxmd.com/read/28967792/abatacept-and-granulocyte-colony-stimulating-factor-in-a-patient-with-rheumatoid-arthritis-and-neutropenia
#20
Marta Priora, Simone Parisi, Marco Scarati, Richard Borrelli, Clara Lisa Peroni, Enrico Fusaro
Neutropenia in patients with inflammatory diseases increases the risk of infection due to the disease itself and the related immunosuppressive treatments. We report the case of a 54-year-old female with rheumatoid arthritis and following development of chronic neutropenia. All investigations excluded pathogenic relations with drugs and/or other clinical situations; the gravity of neutropenia required a treatment with G-CSF and the increased articular inflammatory activity justified a biologic-therapy, abatacept (CTLA4 inhibitors)...
October 2017: Immunotherapy
keyword
keyword
34738
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"